Review of Analytical Method for Quantitative Estimation of Metformin Hydrochloride and Evogliptin Tartrate, A New DPP-4 Inhibitor in Pharmaceutical Dosage Form

Keywords: Analytical methods, Metformin Hydrochloride, Evogliptin Tartrate, UV-Visible Spectrophotometer, RP-HPLC, HPTLC, Stability-indicating RP-HPLC Method

ABSTRACT

Metformin Hydrochloride, also known as 3-(diaminomethylidene)-1,1-dimethylguanidine; hydrochloride, is an oral antihyperglycemic agent and an effective biguanide. Metformin hydrochloride is primarily used as a first-line treatment for type II diabetes mellitus to control blood glucose levels (non-insulin-dependent). Evogliptin tartrate is a Dipeptidal peptidase-4 inhibitor that is taken orally. It is also known chemically as (3R)-4-[(3R)-3-amino-4-(2,4,5 trifluorophenyl)] [(2-methylpropan-2-yl) ox methyl] -3-[(2-methylpropan-2-yl) ox methyl] piperazin-2-one;(2R,3R) Its chemical name is 2,3-dihydroxybutanedioic acid, and it is used to improve glycemic control primarily by stimulating glucose-mediated incretin increased insulin secretion and decreased glucagon release, resulting in a lower risk of hypoglycemia. The new combined strategy for type 2 diabetes mellitus medication adherence was not developed. This review focuses on recent advances in analytical techniques for estimating Evogliptin Tartrate and Metformin Hydrochloride, as there has been no approach for this combination described too far. However, for Metformin Hydrochloride alone and in combination with other medications, HPLC, UV, Stability indicating HPTLC and Stability-indicatingRP-HPLC methods have been described, however for Evogliptin Tartrate, just one HPLC and UV Spectrophotometric method has been reported recently.

Rajasekaran Aiyalu¹, I. Ponnilavarasan², Nidhil Rajan³*, Haribhuvanesh⁴

1 Professor, Department of Pharmaceutical Analysis, KMCH College of Pharmacy, Coimbatore-641048, Tamilnadu, India.

2 Associate Professor, Department of Pharmaceutical Analysis, KMCH College of Pharmacy, Coimbatore-641048, Tamilnadu, India.

3, 4 Research Students, Department of Pharmaceutical Analysis, KMCH College of Pharmacy, Coimbatore-641048, Tamilnadu, India.

Submitted: 20 October 2021
Accepted: 25 October 2021
Published: 30 November 2021
INTRODUCTION

Type 2 diabetes is also known as Non-Insulin-Dependent Diabetes, and it affects 90-95 percent of diabetic patients. Metformin Hydrochloride is recommended as the first-line therapy for type 2 diabetes, followed by the addition of second-line medicines to Metformin Hydrochloride for individuals with insufficient control of hyperglycemia. DPP-4 inhibitors are a very new and developing class of therapy option among the added second-line medications. Example of DDP-IV inhibitors are Vildagliptin, Sitagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, Alogliptin, Trelagliptin, Omarigliptin, Evogliptin.

Metformin Hydrochloride, also known as 3-(diaminomethylidene)-1,1-dimethylguanidine; hydrochloride, is an effective biguanide class oral antihyperglycemic medication. Metformin hydrochloride has long been considered the first-line medication for non-insulin-dependent diabetic mellitus (type II) blood glucose control.

Metformin hydrochloride works by activating the enzyme AMP-activated protein kinase (AMPK), which reduces hepatic glucose synthesis (gluconeogenesis) and hence lowers blood glucose levels. It reduced glucose absorption in the intestine while improving insulin sensitivity, which improved peripheral glucose uptake and utilization. It disrupts the mitochondrial respiratory chain and increases anaerobic glycolysis for peripheral glucose utilization. It encourages weight loss rather than weight gain and is used to reduce the risk of macrovascular and microvascular complications in people with diabetes. [1,2]

![Classification of Antidiabetic Drug](image)

**Figure no 1: Classification of Antidiabetic Drug.**

*Citation: Nidhil Rajan et al. Ijppr.Human, 2021; Vol. 22 (4): 173-191.*
Dong-A ST recently discovered Evogliptin Tartrate, a new oral DPP-4 inhibitor for the treatment of type 2 diabetes. Chemically, it's known as (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl) butanoyl]-3-[(2-methylpropan-2-yl) oxy methyl] piperazin-2-one;(2R,3R)-2,3-dihydroxybutanedioic acid. Evogliptin Tartrate is used to improve glycaemic control by stimulating glucose-mediated incretin secretion, resulting in increased insulin secretion and decreased glucagon release with a lower risk of hypoglycemia. It also has a positive effect on metabolic abnormalities such as obesity, hypertension, and dyslipidemia, all of which are linked to type 2 diabetes (non-insulin-dependent diabetes mellitus).

Evogliptin Tartrate has a long half-life (30 hours), and its pharmacokinetics are unaffected by meals, and its inhibitory effect on DPP-4 activity lasts for 24 hours. When compared to taking two individual component tablets, which reduce polypharmacy and improve patient compliance, the fixed-dose combination formulation of Metformin Hydrochloride and Evogliptin Tartrate may improve therapeutic effect in a patient with insufficient control of hyperglycemia by improving medication adherence. [3]

**DPP-IV inhibitors**

DPP-IV (dipeptidyl peptidase-IV) inhibitors are a new type of diabetes medication. Patients with type 2 diabetes who haven't responded well to sulphonylureas or metformin are prescribed gliptins, also known as DPP-IV. Weight loss and blood glucose control are aided by dipeptidyl peptidase-IV inhibitors, but they've also been related to an increased risk of pancreatitis.

They function by inhibiting DPP-IV, an enzyme that breaks down incretins (a group of gastrointestinal hormones). Incretins help the liver reduce glucagon production when it's not needed (e.g., after eating) and stimulate insulin synthesis when it's needed (e.g., during digestion).

They also suppress hunger and cause digestion to take longer. DPP-IV inhibitors help to manage blood glucose levels by protecting incretins from destruction.[4] They don't produce hypoglycemia unless they're taken with other hypoglycemic therapies.[4,5] DPP-IV inhibitors can be used as a second or third-line treatment for patients with type -II diabetes after metformin and sulphonylureas, as an alternative to thiazolidinediones.[5,6]
**Figure no 2: Mechanism of DPP-4 inhibitors.**

**Pharmacology Pharmacokinetics**

**Absorption**

Evogliptin has a bioavailability of greater than 50% after a single oral dosage. The administration of evogliptin with food does not affect its absorption. After a single oral administration of evogliptin at doses of 1.25–60 mg, the time to acquire maximum concentration (t C max) was 3–5.5 hours in healthy people.

After a single oral dosage of evogliptin, the maximum plasma concentration (C max) in healthy volunteers was 5.6 ± 1.3 g/l at a dose of 5 mg. C max and the area under the concentration-time curve (AUC last) increase as the dose is increased.

After repeated oral administrations of evogliptin at dosages of 5 mg, 10 mg, and 20 mg once a day, a stable state was obtained by the third day of therapy.

After attaining a steady-state, Cmax of evogliptin was reported about 4-5 hours after drug administration.

**Distribution**

Evogliptin distribution in plasma and whole blood is nearly identical; roughly 46% of evogliptin binds to plasma proteins.

According to non-clinical research, evogliptin is rapidly disseminated in bodily tissues (except heart tissue and the mesentery). Evogliptin was discovered in the foetal bloodstream. Evogliptin was found to be absent in the milk of nursing rats.
Metabolism

The complete drug makes up the majority of evogliptin in circulation (more than 80 percent). The biotransformation pathway produces five metabolites that are primarily present in urine and plasma and have no inhibitory impact on DPP-IV.

CYP3A4 is frequently involved in the metabolism of evogliptin. Evogliptin did not stimulate CYP1A2, 2B6, 3A4 enzymes and did not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4 enzymes, according to in vitro tests.

Excretion

The average elimination half-life (t1/2) after a single administration of evogliptin ranged from 32.5 to 39.8 hours at doses of 1.25-60 mg.

After many administrations, the average excretion half-life ranged from 32.9 to 38.8 hours.

In healthy adult volunteers, 42.8 percent of the dosage is removed through feces (including metabolites), and 46.1 percent is eliminated by urine.

Dosing

Evogliptin is usually taken once a day by adults at a dose of 5 mg. Pediatric Use: The safety and efficacy in children have yet to be verified.

There hasn't been nearly enough research into the care of elderly individuals.

Because the elderly's physiological capabilities, such as renal and hepatic functions, are frequently compromised, caution should be exercised during administration while keeping an eye on the patient's health.

Therapeutic Indication

If used as a monotherapy or in conjunction with metformin, for the treatment of type -II diabetes mellitus as an adjuvant to exercise and diet to improve glycaemic control.
Contraindication

Type 1 diabetes, intense ketosis, diabetic coma, or pre-coma are not approved for people who have a hypersensitivity to the medicine or any of its ingredients.

Side effects

Hypoglycemia with insulin or a sulfonylurea, throat irritation, and upper respiratory tract infection.

Safety Information [7]

1. Heart failure

The New York Heart Association (NYHA) has not approved the use of evogliptin in individuals with functional class II-IV due to a lack of clinical research in these patients.

2. Renal impairment

Around 46.1 percent of the administered radioactivity was removed in urine, while 42.8 percent was excreted in feces in healthy adults. It includes the original form as well as its metabolites.

3. Hepatic impairment

In patients with hepatic impairment, no research was done.

4. Acute pancreatitis

Acute pancreatitis has not been documented among evogliptin users. Acute pancreatitis can cause continual, strong abdominal discomfort, which patients should be aware of evogliptin should be stopped if pancreatitis is suspected; it should not be reintroduced if acute pancreatitis is confirmed. Patients who have had pancreatitis in the past should be handled with caution.

Use during Pregnancy and Lactation

Use in pregnant women
For pregnant women, there are no comparable research findings. In animal testing, evogliptin was discovered in the bloodstream of the fetus through the placenta is up to 61.7 percent of pregnant rats and 14.1 percent of pregnant rabbits two hours after injection. As a result, it is not recommended that pregnant women be used.

Use in nursing women

It has not been established how much evogliptin is excreted in human milk. Animal investigations have revealed that evogliptin is secreted in milk, hence it cannot be used by breastfeeding mothers.[8]

Drug-Drug Interaction

The enzyme CYP3A4 is responsible for the majority of evogliptin metabolism. The CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4 enzymes were shown to be neither inhibitors nor inducers by evogliptin. Other medications that serve as substrates are unlikely to interact with evogliptin enzymes of this type.

Interaction of evogliptin with other drugs

**Metformin**: The pharmacokinetics of evogliptin 5 mg and metformin 1,000 mg twice daily (an OCT1 and OCT2 substrate) did not improve clinically appreciably until they reached a steady state. [8]

**Clarithromycin**: When compared to multiple administration of potential CYP3A4 inhibitor clarithromycin at a daily dose of 1,000 mg until the steady concentration was reached, a single administration of evogliptin at a dose of 5 mg resulted in a 2.17 -fold increase in evogliptin Cmax and a 2.02-fold increase in evogliptin AUC. When given with a CYP3A4 inhibitor, the pharmacokinetic characteristics of evogliptin can rise, hence caution is advised. [9]

Physical and Chemical property

Metformin hydrochloride is a crystalline powder that is white or nearly white.

3-(diaminomethylidene)-1,1-dimethylguanidine is the IUPAC designation for metformin hydrochloride (Fig.1.). Metformin hydrochloride has the chemical formula C4H11N5, HCl.
165.6 gm/mol is the molecular weight. Water is easily soluble; alcohol is somewhat soluble, while ether, chloroform, acetone, and methylene chloride are practically insoluble.

**Chemical structure of metformin hydrochloride** [10]

Evogliptin Tartrate is a white powder that is used to treat diabetes. Evogliptin tartrate's IUPAC name is (3R)-4-[(3R)-3- amino-4-(2,4,5-trifluorophenyl) butanoyl]-3-[(2 methyl propan-2-yl) ox methyl] piperazin-2- one;(2R,3R)-2,3-dihydroxybutanedioic acid. Evogliptin tartrate has the chemical formula C23H32F3N3O9. The molecular weight of this compound is 551.5 gm/mol. It's soluble in water, dimethyl sulfoxide, and methanol, but essentially insoluble in acetone and chloroform.

**Chemical structure of evogliptin tartrate** [11]

**Analytical methods**

The creation and validation of analytical methods are critical in the discovery, development, and production of pharmaceutical products. The process of showing that an analytical method is suitable for measuring API content in certain compounded dosage forms is known as method development.

Every year, the number of pharmaceuticals that are added to the market grows. Because these medications may be a novel moiety or a structural alteration of an existing one, analytical
Methodologies for the new drugs may not be available in pharmacopeias. As a result, newer analytical methods for such medications are required. Quality control laboratories utilize official test procedures to assure the identification, purity, potency, and performance of drug goods. UV Spectrophotometry, High-Performance liquid chromatography, High-Performance thin layer chromatography, Ultra performance liquid spectrometry, and Stability indicating High-Performance liquid chromatography, LC-MS/MS, spectrofluorimetry, GC/MS, etc. are some of the technologies used to analyze the analyte. [12-13]

After doing a literature review on the development and validation of analytical methods for Metformin Hydrochloride and Evogliptin Tartrate, it was discovered that no method has been reported for this combination to date. However, for Metformin Hydrochloride alone and in combination with other medications, UV, HPLC, Stability indicating RP- HPLC and HPTLC methods have been described, however for Evogliptin Tartrate, only one UV Spectrophotometric method has been documented.

**Table no. 1: Official methods for estimation of metformin hydrochloride.**

<table>
<thead>
<tr>
<th>Sr. no.</th>
<th>Official in</th>
<th>Methods</th>
<th>Description</th>
<th>Ref. no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Indian Pharmacopoeia 2018</td>
<td>Liquid Chromatography</td>
<td><strong>Stationary Phase:</strong> A stainless steel column 30 cm x 4 mm, packed with octadecylsilane bonded to porous silica (10 μm)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Mobile Phase:</strong> A solution containing 0.087 % w/v of Sodium pentane sulphonate and 0.12% w/v of sodium chloride, adjusted to pH 3.5 using 1% v/v solution of orthophosphoric acid.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Flow rate:</strong> 1 ml/min.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Wavelength:</strong> 218 nm</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Injection volume:</strong> 20µl</td>
<td>[14]</td>
</tr>
</tbody>
</table>
| 2 | British Pharmacopoeia 2003 | Liquid Chromatography | Stationary phase:  
Size = 0.25 m, Ø = 4.6 mm  
Stationary phase: irregular, porous silica gel to which benzenesulphonic acid groups have been chemically bonded (10 µm)  
Or  
Size = 0.11 m, Ø = 4.7 mm;  
Stationary phase: regular, porous silica gel to which benzenesulphonic acid groups have been chemically bonded (5 µm).  
Mobile phase: 17 g/l solution of ammonium dihydrogen phosphate R adjusted to pH 3.0 with phosphoric acid R  
Flow rate: 1 ml/min  
Wavelength: 218 nm  
Injection volume: 20µl |

Table no. 2: Reported methods for estimation of metformin hydrochloride.

<table>
<thead>
<tr>
<th>Sr. no.</th>
<th>Method</th>
<th>Description</th>
<th>Ref. no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Development and validation of UV spectroscopic method for the determination of Metformin Hydrochloride in tablet dosage form.</td>
<td>Model: Shimadzu UV mini 1700 Solvent: 0.01N NaOH Wavelength: 233 nm Linearity: 1-25 µg/ml</td>
<td>[17]</td>
</tr>
</tbody>
</table>

### Condition % Degradation

<table>
<thead>
<tr>
<th>Sr. no.</th>
<th>Condition</th>
<th>% Degradation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Acid</td>
<td>15.84</td>
</tr>
<tr>
<td>2</td>
<td>Alkali</td>
<td>18.94</td>
</tr>
<tr>
<td>3</td>
<td>Thermal</td>
<td>3.31</td>
</tr>
<tr>
<td>4</td>
<td>UV(254nm)</td>
<td>9.51</td>
</tr>
<tr>
<td>5</td>
<td>UV(365nm)</td>
<td>212.12</td>
</tr>
<tr>
<td>6</td>
<td>3% H2O2</td>
<td>22.14</td>
</tr>
</tbody>
</table>

### %Degradation

<table>
<thead>
<tr>
<th>Sr.no</th>
<th>Condition</th>
<th>Time</th>
<th>% Degradation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.1N NaOH</td>
<td>60min</td>
<td>8.07</td>
</tr>
<tr>
<td></td>
<td></td>
<td>90min</td>
<td>11.95</td>
</tr>
<tr>
<td>2</td>
<td>3N HCl</td>
<td>60 min</td>
<td>9.75</td>
</tr>
<tr>
<td></td>
<td></td>
<td>90min</td>
<td>12.79</td>
</tr>
<tr>
<td>3</td>
<td>30% H2O2</td>
<td>15 min</td>
<td>12.65</td>
</tr>
<tr>
<td>4</td>
<td>Dry Heat (70°C)</td>
<td>48 hrs</td>
<td>20.94</td>
</tr>
<tr>
<td>5</td>
<td>Photolytic</td>
<td>3 hrs</td>
<td>10.53</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Development and validation of UV spectrophotometric method for simultaneous estimation of <strong>Empagliflozin and Metformin Hydrochloride</strong> in combined dosage form.</th>
<th>Model: Elico SL 210  <strong>Solvent:</strong> Methanol and Water  <strong>Wavelength</strong>  <strong>Simultaneous equation method:</strong> Empagliflozin: 224 nm Metformin Hydrochloride: 233 nm  <strong>Absorbance ratio method:</strong> Iso-absorptive Point: 266 nm Metformin Hydrochloride: 233 nm  <strong>Linearity:</strong> Empagliflozin: 0.1-25 µg/ml Metformin Hydrochloride: 0.5-25 µg/ml</th>
<th>[21]</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>Development and validation of UV-Visible spectroscopy method for simultaneous estimation of <strong>Saxagliptin Hydrochloride and Metformin Hydrochloride</strong> in tablet dosage form.</td>
<td>Model: Jasco V-630  <strong>Solvent:</strong> Methanol and Distilled water  <strong>Wavelength</strong> Metformin Hydrochloride: 231 nm Saxagliptin: 274 nm  <strong>Linearity:</strong> Metformin Hydrochloride: 2-10 µg/ml Saxagliptin: 50-90 µg/ml</td>
<td>[22]</td>
</tr>
<tr>
<td>8</td>
<td>Development and Validation of UV Spectrophotometric Method for Simultaneous Estimation of <strong>Metformin and Glipizide</strong> in Tablet dosage form.</td>
<td>Model: Shimadzu 1800s  <strong>Solvent:</strong> Distilled water  <strong>Wavelength</strong> Metformin Hydrochloride: 272 nm Glipizide: 232 nm  <strong>Linearity:</strong> Metformin Hydrochloride: 5-25 µg/ml Glipizide: 20-50 µg/ml</td>
<td>[23]</td>
</tr>
<tr>
<td>9</td>
<td>Analytical method development and validation for simultaneous estimation of <strong>Teneligliptin Hydrobromide Hydrate and Metformin Hydrochloride</strong> from its pharmaceutical dosage form by three different UV spectrophotometric methods.</td>
<td>Model: Shimadzu 1800  <strong>Solvent:</strong> Methanol  <strong>Wavelength</strong>  <strong>Simultaneous equation method:</strong> Metformin Hydrochloride: 237 nm Teneligliptin Hydrobromide Hydrate: 246 nm  <strong>Absorbance ratio method:</strong> Iso-absorptive Point: 247.5 nm Metformin Hydrochloride: 237 nm  <strong>First derivative method:</strong> Zero-crossing Points: Metformin Hydrochloride: 237 nm Teneligliptin Hydrobromide Hydrate: 246 nm  <strong>Linearity:</strong> Metformin Hydrochloride: 1-20 µg/ml Teneligliptin Hydrobromide Hydrate: 1-20 µg/ml</td>
<td>[24]</td>
</tr>
<tr>
<td>10</td>
<td>Development and validation of analytical method for simultaneous estimation of Glibenclamide and Metformin Hydrochloride in bulk and tablets using UV-Visible spectroscopy. Model: Shimadzu 1800 Solvent: 0.01N NaOH Wavelength Metformin Hydrochloride: 233 nm Glibenclamide: 226.60 nm Linearity: Metformin Hydrochloride: 2-10 µg/ml Glibenclamide: 3-15 µg/ml</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Analytical Method Development and Validation of Metformin Hydrochloride by using RP-HPLC with ICH Guidelines. Stationary phase: Cosmosil C_{18} (250mm x 4.6mm; 5µm) Mobile phase: Methanol: Phosphate buffer (pH-3) (70:30 %v/v) Flow rate: 1 ml/min Wavelength: 238 nm Linearity: 10-50 µg/ml Retention time: 4.2 min</td>
<td>29</td>
<td></td>
</tr>
</tbody>
</table>
| 15 | RP-HPLC Analytical Method Development and Validation of **Metformin Hydrochloride Tablets Assay** | **Stationary phase:** Hypersil ODS C18, (250mm x 4.6mm; 5µm)  
**Mobile phase:** Acetonitrile: Phosphate buffer (pH-5.75) (65:35 %v/v)  
**Flow rate:** 1.0 ml/min  
**Wavelength:** 233 nm  
**Linearity:** 50-150 μg/ml  
**Retention time:** 7.168 min | [30] |
| 16 | Development and Validation of a RP-HPLC Method for the Determination of **Metformin Hydrochloride** in Pharmaceutical Dosage Forms. | **Stationary phase:** Zorbax-SCX C18, (250mm x 4.6mm; 5µm)  
**Mobile phase:** Ammonium-dihydrogen phosphate buffer (pH-3): Acetonitrile (50:50 %v/v)  
**Flow rate:** 1 ml/min  
**Wavelength:** 218 nm  
**Linearity:** 20-60 µg/ml  
**Retention time:** 11.12 min | [31] |
| 17 | Simple and sensitive analytical method development and validation of **Metformin Hydrochloride** by RP-HPLC. | **Stationary phase:** Inertsil-Extend C18, (250mm x 4.6mm; 5µm)  
**Mobile phase:** 1-Octane sulfonic acid: Acetonitrile (80:20 %v/v)  
**Flow rate:** 1 ml/min  
**Wavelength:** 232 nm  
**Linearity:** 1-250 µg/ml  
**Retention time:** 10.78 min | [32] |
| 18 | Development and validation of RP-HPLC method for simultaneous estimation of **Metformin Hydrochloride and Glipizide** in bulk and pharmaceutical dosage form. | **Stationary phase:** Cosmosil C18, (250mm x 4.6mm; 5µm)  
**Mobile phase:** Methanol: Water (60:40 %v/v) (pH 3 adjusted with orthophosphoric acid)  
**Flow rate:** 0.8ml/min  
**Wavelength:** 226 nm  
**Linearity:**  
Glipizide: 1-5 µg/ml  
Metformin Hydrochloride: 100-500 µg/ml  
**Retention time:**  
Glipizide: 5.571 min  
Metformin Hydrochloride: 4.159 min | [33] |
| 19 | Development and validation of a new analytical HPLC method for simultaneous determination of the antidiabetic drugs, **Metformin and Gliclazide**. | **Stationary phase:** Alltima CN (250mm x 4.6mm; 5µm)  
**Mobile phase:** 20 mM ammonium formate buffer (pH 3.5): Acetonitrile (45:55 %v/v)  
**Flow rate:** 1 ml/min  
**Wavelength:** 227nm  
**Linearity:**  
Metformin: 2.5-150 µg/ml  
Gliclazide: 1.25-150µg/ml  
**Retention time:**  
Metformin: 6.9 min  
Gliclazide: 4.1 min | [34] |
<table>
<thead>
<tr>
<th>Page</th>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>Development and validation of analytical method for simultaneous estimation of <strong>Saxagliptin and Metformin Hydrochloride</strong> by using RP-HPLC method.</td>
<td><strong>Stationary phase:</strong> Waters C8, (250mm x 4.6mm; 5μm)&lt;br&gt;<strong>Mobile phase:</strong> Methanol: Phosphate buffer (pH-5.0) (70:30 %v/v)&lt;br&gt;<strong>Flow rate:</strong> 1 ml/min&lt;br&gt;<strong>Wavelength:</strong> 228 nm&lt;br&gt;<strong>Linearity:</strong> Metformin Hydrochloride: 250-1250 μg/ml&lt;br&gt;Saxagliptin: 2.5-12.5 μg/ml&lt;br&gt;<strong>Retention time:</strong> Metformin Hydrochloride: 2.8 min&lt;br&gt;Saxagliptin: 4.9 min</td>
</tr>
<tr>
<td>21</td>
<td>Method development and validation of simultaneous estimation of <strong>Alogliptin and Metformin Hydrochloride</strong> by RP-HPLC.</td>
<td><strong>Stationary phase:</strong> Agilent C18 G, (150mm x 4.6mm; 5μm)&lt;br&gt;<strong>Mobile phase:</strong> Phosphate buffer (pH-3.0 adjusted with 0.1% OPA) : methanol (20:80 %v/v)&lt;br&gt;<strong>Flow rate:</strong> 0.7 min/ml&lt;br&gt;<strong>Wavelength:</strong> 242 nm&lt;br&gt;<strong>Linearity:</strong> 10-30 μg/ml&lt;br&gt;<strong>Retention time:</strong> Metformin Hydrochloride: 1.727 min&lt;br&gt;Alogliptin: 2.9 min</td>
</tr>
<tr>
<td>22</td>
<td>RP-HPLC Method development and validation for the Simultaneous Estimation of <strong>Metformin and Canagliflozin</strong> in Tablet Dosage Form.</td>
<td><strong>Stationary phase:</strong> ODS (250mm x 4.6mm; 5μm)&lt;br&gt;<strong>Mobile phase:</strong> Buffer : Acetonitrile : methanol (40:40:20 %v/v/v)&lt;br&gt;<strong>Flow rate:</strong> 1 ml/min&lt;br&gt;<strong>Wavelength:</strong> 212 nm&lt;br&gt;<strong>Linearity:</strong> Metformin: 50-300 μg/ml&lt;br&gt;Canagliflozin: 5-30 μg/ml&lt;br&gt;<strong>Retention time:</strong> Metformin: 2.783 min&lt;br&gt;Canagliflozin: 3.781 min</td>
</tr>
<tr>
<td>23</td>
<td>Development and Validation of RP-HPLC Method for Simultaneous Estimation of <strong>Metformin and Linagliptin</strong> in Combined Pharmaceutical Dosage Form.</td>
<td><strong>Stationary phase:</strong> Hypersil BDS C18, (250mm x 4.6mm; 5μm)&lt;br&gt;<strong>Mobile phase:</strong> Potassium dihydrogen phosphate (KH2PO4): Acetonitrile (40:60 %v/v)&lt;br&gt;<strong>Flow rate:</strong> 1 ml/min&lt;br&gt;<strong>Wavelength:</strong> 250 nm&lt;br&gt;<strong>Linearity:</strong> Metformin Hydrochloride: 100-600 μg/ml</td>
</tr>
</tbody>
</table>
Official method for estimation of evogliptin tartrate

There is no official method for Evogliptin tartrate in any pharmacopeia.

Table no. 3: A reported method for estimation of evogliptin tartrate.

<table>
<thead>
<tr>
<th>Sr. no.</th>
<th>Method</th>
<th>Description</th>
<th>Ref. no.</th>
</tr>
</thead>
</table>
| 1       | Development and Validation of RP-HPLC Method for estimation of Evogliptin in Pharmaceutical Dosage Form. | **Stationary phase:** Column C18, 5 μm, (250 X 4.6 mm)  
**Mobile Phase:** methanol:water:acetonitrile (70:20:10)  
**Wavelength:** 265 nm  
**Linearity:** 10–30 μg/ml.  
80775 X – 21004,  
**Rf value:** 0.99 | [39] |
| 2       | Development and Validation of Novel UV Spectrophotometric Method for the Determination of Evogliptin tartrate in Pharmaceutical Dosage Form. | **Solvent:** Deionized water  
**Wavelength:** 267 nm  
**Linearity:** 10-100 μg/ml | [40] |

**SUMMARY**

The analysis of published data revealed that there was no method reported for Metformin Hydrochloride and Evogliptin Tartrate fixed-dose combination. According to the literature review, it has been concluded that different spectroscopic methods like UV, HPLC, Stability indicating RP-HPLC, and HPTLC methods have been reported for Metformin Hydrochloride individual and along with other drugs and for Evogliptin Tartrate only one UV Spectrophotometric method has been reported. So there is scope to develop different analytical methods for the combination of Metformin Hydrochloride alone and Evogliptin Tartrate. This review carried out an overview of the current state-of-art analytical methods for the determination of Metformin hydrochloride and Evogliptin tartrate, which will be supportive for further research on this combination. The review would also help to know the key solvents and their available set of instruments in the analytical laboratory. The methods are also helpful for in-process evaluation during the manufacturing of API.
REFERENCES

